Psychiatric Drug Active Pharmaceutical Ingredients →Shortage risk
Antidepressants and mental health medications
This is a critical upstream input (dependency strength 0.98), so a production halt in the API market directly tightens supply of these medicines.
96% confidence
ABF Substrate (Ajinomoto Build-up Film) →Shortage risk
Ajinomoto Fine-Techno
ABF substrate is a sole-qualified, 95% share input for Ajinomoto Fine-Techno with a 60-month replacement lead time, so a halt materially constrains its supply.
94% confidence
Acetaminophen (APAP) API →Shortage risk
OTC medicines
Acetaminophen API is a critical input to OTC medicines, so a plant shutdown and recall materially reduces finished-product availability.
93% confidence
Bisphenol A-Based Liquid Epoxy Resin (BPA-LER) →Shortage risk
Paint and architectural coatings
BPA-LER is a critical input for paint and architectural coatings, so a production halt upstream should constrain coatings supply.
92% confidence
ABF Substrate (Ajinomoto Build-up Film) →Shortage risk
Ajinomoto Co.
Ajinomoto Co.'s 90% share exposure suggests a dominant dependence on the ABF substrate flow, so the halt constrains its supply.
91% confidence
Copper Clad Laminate (CCL/FR-4) →Shortage risk
Computers and laptops
Computers and laptops have the strongest listed dependency on CCL/FR-4, so the input disruption should directly tighten supply.
88% confidence
Synthetic Footwear Upper Material (PU/PET) →Shortage risk
Footwear
A production halt in a critical PU/PET upper-material input should tighten supply to footwear manufacturers, and this edge is marked as high-dependency and critical.
88% confidence
ABF Substrate (Ajinomoto Build-up Film) →Shortage risk
Servers and cloud hardware
Servers and cloud hardware are marked as critically dependent on this input, so the halt should tighten downstream hardware availability.
88% confidence
Copper Clad Laminate (CCL/FR-4) →Shortage risk
GPUs and AI accelerators
CCL/FR-4 is a critical direct input for advanced accelerator boards, so a CCL supply halt reduces availability of GPUs and AI accelerators.
86% confidence
ABF Substrate (Ajinomoto Build-up Film) →Shortage risk
IbidenIBIDF
Ibiden has a 25% dependence on this input and a 24-month replacement horizon, making the shutdown a meaningful supply hit.
84% confidence
Bisphenol A-Based Liquid Epoxy Resin (BPA-LER) →Shortage risk
Taiwan
The halted Nan Ya operation is in Taiwan, and Taiwan carries a 12% BPA-LER supply share, so the country's supply availability is directly hit.
84% confidence
Copper Clad Laminate (CCL/FR-4) →Shortage risk
Smartphones and tablets
Smartphone and tablet production depends materially on CCL/FR-4, so a laminate shortage constrains finished-device output.
84% confidence
Acetaminophen (APAP) API →Shortage risk
Farmson Pharmaceutical
Farmson has a sizable APAP API share and the low substitutability plus 12-month replacement lead time make near-term supply disruption likely.
83% confidence
Acetaminophen (APAP) API →Shortage risk
Anqiu Lu'an Pharmaceutical
Anqiu Lu'an's meaningful APAP API share and limited substitutability imply a real downstream supply squeeze if this API is constrained.
82% confidence
Acetaminophen (APAP) API →Shortage risk
Granules IndiaGRANULES
Granules India depends on APAP API with a material market share and a 12-month replacement horizon, so output pressure is likely.
81% confidence
ABF Substrate (Ajinomoto Build-up Film) →Shortage risk
Unimicron Technology3037.TW
Unimicron Technology's 18% share dependence means the ABF substrate outage can reduce its available supply and delay output.
81% confidence
Acetaminophen (APAP) API →Shortage risk
Hebei Jiheng Pharmaceutical Co., Ltd.
Hebei Jiheng is less exposed than the largest buyers, but the APAP API interruption still constrains supply given long replacement times.
80% confidence
ABF Substrate (Ajinomoto Build-up Film) →Shortage risk
Shinko Electric Industries
Shinko Electric Industries relies on this input for 12% of supply, so the production halt creates a smaller but real shortage risk.
78% confidence
UroGen Pharma Ltd. →Prices ease
Teva Pharmaceutical Industries Ltd.TEVA
Because UroGen says Teva is its single-source supplier of mitomycin API for several products, a shutdown and recall at UroGen can temporarily eliminate Teva’s offtake and pressure API prices lower.
74% confidence
Purified Terephthalic Acid (PTA) — PET Plastic Monomer →Stands to benefit
Indorama VenturesIVL.BK
As a major PTA supplier with a 20% market share, Indorama can capture some displaced demand when Nan Ya's PTA output is halted.
74% confidence
Purified Terephthalic Acid (PTA) — PET Plastic Monomer →Stands to benefit
Zhejiang Rongsheng Petrochemical002493
Zhejiang Rongsheng is a sizable substitute PTA supplier, so a shutdown at Nan Ya can modestly shift orders toward it.
72% confidence
Purified Terephthalic Acid (PTA) — PET Plastic Monomer →Stands to benefit
Sinopec (China Petrochemical Corp.)0386.HK
Sinopec's PTA supply share makes it a likely partial beneficiary of diverted PTA purchases after the halt.
71% confidence
Purified Terephthalic Acid (PTA) — PET Plastic Monomer →Stands to benefit
BP plcBP
BP can benefit as a substitute PTA supplier when a competitor's production is interrupted.
69% confidence
Purified Terephthalic Acid (PTA) — PET Plastic Monomer →Stands to benefit
Lotte Chemical Corporation011170
Lotte is another PTA supplier that may gain a small amount of displaced demand from the shutdown.
66% confidence
Synthetic Footwear Upper Material (PU/PET) →Stands to benefit
Kuraray3405.T
As a qualified supplier of the same input, Kuraray can capture some displaced demand from Nan Ya's shutdown, though the moderate substitutability and six-month replacement horizon limit the effect.
58% confidence
Synthetic Footwear Upper Material (PU/PET) →Stands to benefit
Toray Industries, Inc.3402.T
Toray is another qualified supplier that may absorb some diverted orders when Nan Ya's output is constrained, but the substitution is only partial.
56% confidence
Psychiatric Drug Active Pharmaceutical Ingredients →Stands to benefit
Teva API (TAPI)TEVA
As a 12% share alternative supplier with moderate substitutability, Teva can absorb some rerouted sourcing from the disrupted API, although the 12-month replacement lead time limits the near-term gain.
56% confidence
Synthetic Footwear Upper Material (PU/PET) →Stands to benefit
Covestro AGCOV
Covestro could benefit from customers re-sourcing away from the halted supplier, but the effect is limited by only moderate substitutability.
56% confidence
